Northland Capmk Comments on Indivior PLC’s FY2024 Earnings (NASDAQ:INDV)

Indivior PLC (NASDAQ:INDV) – Stock analysts at Northland Capmk cut their FY2024 EPS estimates for shares of Indivior in a research note issued to investors on Tuesday, September 17th. Northland Capmk analyst C. Byrnes now anticipates that the company will earn $1.58 per share for the year, down from their prior estimate of $1.60. The consensus estimate for Indivior’s current full-year earnings is $1.70 per share.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.04. The business had revenue of $299.00 million for the quarter, compared to analyst estimates of $285.90 million. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%.

Other analysts also recently issued research reports about the stock. Piper Sandler restated an “overweight” rating and set a $22.00 price objective on shares of Indivior in a report on Friday, September 13th. Craig Hallum cut their price objective on shares of Indivior from $37.00 to $24.00 and set a “buy” rating for the company in a research report on Wednesday, July 10th.

Indivior Stock Performance

NASDAQ INDV opened at $9.48 on Thursday. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.85 and a quick ratio of 0.68. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of 948.00 and a beta of 0.68. Indivior has a 1 year low of $9.14 and a 1 year high of $23.22. The company has a fifty day moving average price of $11.69 and a 200-day moving average price of $15.92.

Institutional Investors Weigh In On Indivior

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp bought a new position in Indivior in the second quarter worth $188,000. VELA Investment Management LLC purchased a new position in shares of Indivior in the 2nd quarter worth $235,000. XTX Topco Ltd bought a new stake in shares of Indivior during the 2nd quarter valued at about $249,000. Chilton Investment Co. Inc. purchased a new stake in Indivior during the fourth quarter valued at approximately $263,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Indivior in the 4th quarter worth $368,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.